If you have started researching medical weight loss, two names come up again and again: semaglutide and tirzepatide. Semaglutide is the active ingredient in Wegovy and Ozempic. Tirzepatide is the active ingredient in Zepbound and Mounjaro. Both are weekly injections, both are among the most studied weight loss medications ever developed, and both work on the hormones that tell your brain you are full. They are not identical, though, and the differences matter when a provider is helping you choose.
How each medication works
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a gut hormone your body releases after eating. It signals fullness to the brain, slows how quickly the stomach empties, and helps the pancreas release insulin when blood sugar rises. Semaglutide mimics that hormone but lasts about a week in the body, which is why it is dosed once weekly.
Tirzepatide acts on two receptors: GLP-1 and GIP. GIP is another gut hormone involved in insulin release and how the body handles fat and energy. Activating both pathways appears to add to the appetite and metabolic effects. Tirzepatide is also dosed once weekly.
In everyday terms, both medications quiet what many patients call food noise, the constant background thoughts about eating. People often describe feeling satisfied with smaller portions and losing interest in snacking between meals.
What the clinical trials showed
Results vary widely from person to person, so it helps to look at averages from large studies rather than individual stories.
- In the STEP 1 trial, adults without diabetes taking semaglutide 2.4 mg weekly lost about 15 percent of their body weight on average over 68 weeks, alongside lifestyle counseling.
- In the SURMOUNT-1 trial, adults taking tirzepatide lost about 15 to 21 percent of body weight on average over 72 weeks, depending on dose.
- In SURMOUNT-5, a head-to-head study, tirzepatide produced greater average weight loss than semaglutide over 72 weeks, roughly 20 percent compared with about 14 percent.
- Both medications have shown improvements in blood sugar, blood pressure and cholesterol markers in many patients.
Higher average weight loss does not automatically make tirzepatide the right choice for everyone. Tolerability, medical history, availability and personal goals all factor in.
FDA approval status, explained plainly
Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Wegovy also carries an approval for reducing the risk of major cardiovascular events in certain adults with heart disease, and Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity.
Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, not for weight loss. Providers sometimes prescribe them off-label, but they are labeled as diabetes medications.
Compounded semaglutide and compounded tirzepatide are prepared by licensed pharmacies and are not FDA-approved. They have not gone through FDA review for safety, effectiveness or quality, which is something every patient should understand before choosing them.
Dosing, side effects and who should avoid them
Titration
Both medications start low and increase gradually, usually every four weeks. Semaglutide for weight loss typically starts at 0.25 mg weekly and steps up toward a 2.4 mg maintenance dose. Tirzepatide typically starts at 2.5 mg weekly and can step up in 2.5 mg increments to as high as 15 mg. Slow titration gives your digestive system time to adjust.
Common side effects
The side effect profiles are similar. Nausea, constipation, diarrhea, reflux, bloating and reduced appetite are the most common, especially during the first weeks and after each dose increase. Some patients find tirzepatide slightly easier on the stomach at comparable effect, while others do better on semaglutide. There is no way to know in advance, which is why follow-up matters.
Who should not use them
Neither medication is appropriate if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, if you are pregnant or trying to become pregnant, or if you have had certain reactions to GLP-1 medications. A history of pancreatitis, gallbladder disease, severe digestive conditions or diabetic eye disease calls for a careful conversation first.
How a provider helps you choose
When a licensed provider reviews your intake, they look at your weight history, BMI, current medications, blood sugar status, past experience with GLP-1s, and any conditions that could change the risk. They also consider practical issues such as how you feel about injections, how quickly you want to progress, and which options are realistically available.
For some patients, semaglutide is a great fit with years of real-world data behind it. For others, tirzepatide offers a stronger average effect. Some start on one and switch later. A good plan includes regular check-ins, dose adjustments based on how you feel, and support with nutrition and protein so the weight you lose is mostly fat rather than muscle.
Talk to a provider
If you are deciding between semaglutide and tirzepatide, the most useful next step is a conversation with someone who can review your full health picture. At Provo Weight Loss, you can get started online with a short questionnaire. A licensed provider reviews your answers, discusses options with you, and prescribes medication only when appropriate. If prescribed, your medication ships from a licensed US pharmacy, and your care team stays in touch through regular check-ins.
Medical disclaimer: This article is for general education only and is not medical advice, so please talk with a licensed provider about your own health.
Thinking about treatment in Provo, UT?
Provo Weight Loss providers review every case online and ship medication across the Provo area when it is appropriate.